Our Business

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and Phosphagenics' ADR's (PPGNY) are traded on the OTCQX in the US.








 

Breaking News

14 December 2011

PHOSPHAGENICS DECEMBER 2011 E-NEWSLETTER AND PLACEMENT OF SHARES

• December 2011 eNewsletter
• Equity Raising

Phosphagenics Limited is pleased to announce that following the approval granted by shareholders at the General Meeting held on 9 December 2011 the Company advises that it has now issued the 50 million new shares at $0.14 a share.  ASX Equity Raising correction.

Phosphagenics Limited Research Reports - RBS Morgans,   Bell Potter Report,   CCZ Equities Research

Click here for Dr Esra Ogru's Sky News feature (11th Jan 2012)

21 November 2011

PHOSPHAGENICS ON TRACK - PIVOTAL TPM OXYCODONE PATCH TRIALS BEGIN

• Precursor to Pivotal Phase 3 Trial
• Optimised Patch to be used in Clinical Trials
• Clinical Trial Results to be included in IND Application

Phosphagenics Limited has been granted ethics approval to begin clinical trials on its leading pharmaceutical product, a TPM/oxycodone patch to manage chronic pain.  The trials will start at the end of
November 2011.


Phosphagenics Limited Media Coverage December 2011


Read our latest news:  December 2011 NEWSLETTER




To view all releases in full please click here